Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Flutemetamol F 18 - GE Healthcare/University of Pittsburgh

Drug Profile

Flutemetamol F 18 - GE Healthcare/University of Pittsburgh

Alternative Names: 18-F Flutemetamol; [18F]flutemetamol; AH-110690; F-18 PiB; F18 flutemetamol; Flutemetamol F18; Flutemetamol F18 Injection; GE 067; Pittsburgh compound B; Vizamyl

Latest Information Update: 08 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Pittsburgh
  • Developer GE Healthcare; University of Pittsburgh
  • Class Aniline compounds; Benzothiazoles; Fluorocarbons; Radiopharmaceutical diagnostics; Small molecules
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Alzheimer's disease

Most Recent Events

  • 23 Oct 2018 Launched for Alzheimer's disease (Diagnosis) in Czech Republic (IV)
  • 02 Oct 2018 GE Healthcare terminates phase III trial in Alzheimer's disease (Diagnosis, In elderly) in the Netherlands (EudraCT2016-002635-15)
  • 24 Jun 2018 Biomarkers information updated
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top